I'm sure there are several "Elanco's" watching this closely now. I also suspect Elanco is kicking itself for walking out a couple of months after the 2020 dog cancer trial because at the time there were still mTOR related issues that potentially could take years, if forever, to overcome, and what do you know, have been overcome. So at this point, the best game plan for PAA is to keep building up its data with trials while "talking" to unnamed potential suitors so as to sound out their wishes and the better to play them off against each other later. Just my opinion of course.
Ann: PharmAust Expands Lymphoma Canine Trial to the USA, page-25
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.12M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.5¢ | $50.92K | 290.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 152309 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 329859 | 3 |
View Market Depth
| Last trade - 15.48pm 11/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |